Superior Determination of HPV using RNAscope™ In Situ Hybridization
The RNAscope™ RNA In Situ Hybridization (ISH) Platform, including chromogenic detection reagents and target-specific probes for both High Risk and Low Risk HPV types, provides clear and unequivocal assessment of active HPV status in FFPE tissue. In numerous peer-reviewed publications, the RNAscope HPV Detection Reagents have demonstrated significantly higher specificity and equivalent sensitivity in direct comparisons with p16 immunohistochemistry (IHC) for the presence of high-risk HPV in oropharyngeal squamous cell carcinoma (OPSCC).
Higher Specificity and Direct Detection of HPV E6/E7 mRNA Increases Confidence
The combination of high sensitivity and high specificity ensures ready identification of HPV-related tumors while reducing potential false positives that can result from the use of surrogate markers of HPV such as p16. Unlike p16 IHC, RNAscope allows the pathologist to evaluate any single HPV type or combination of HPV types through interrogation of HPV E6/E7 viral oncogene mRNA.
